Senores Pharmaceuticals Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/oqh7q1104061zqu5dgm4esoz.pdf

Key Takeaways


Regulated Markets: The Growth Engine

Swapnil Shah: "No product is lying there in our portfolio which is approved and we don't have a commercial strategy mapped out. So that we are very, very clear from day one that anything that we take, either through our own development or on acquisition route, commercial strategy is well defined and mapped."

Emerging Markets: Seasonal Margin Dip, Cash Flow Positive

Swapnil Shah: "Historically, if you look at emerging market business, H2 has always been strong, right? So, we H1 is always been relatively on the lower side. First time, if you picked last four quarters, first quarter last four years, this has been the strongest quarter that we have, we have delivered, you know, from the emerging market business."

India Branded Generics: Profitability Over Top-Line

Swapnil Shah: "The idea is to now how we can how we can get to INR50 crores to INR60 crores sales number with good 35% to 40% EBITDA number. So that has been you'll see the it's kind of little moderated, but from Y-o-Y basis, do we expect that growth of 30% to 40% on branded generics? We are confident of achieving those numbers."

Manufacturing & Capacity: Apnar Ramps, Injectables Scaled Back

Swapnil Shah: "That's a strategic rationalization as a management we took a call and we thought that this could be a better use of our proceeds than creating a completely new greenfield facility and then wait it out for it to scale up and create the opportunities for us."

Tariffs, Mix & Long-Term Roadmap

Swapnil Shah: "We already have a facility in the US. I mean so for us it's a neutral. We have facility on the both the side."

Financial Details: One-Time Items Distort Sequential Comparisons


Guidance & Commitments

CommitmentSpecificsTimeline
FY27 revenue growthApproximately 30% to 40%FY27 full year
FY27 PAT growthAbout 50% to 60%FY27 full year
ANDA commercialization35 ANDAs launchedNext 18 to 20 months
Emerging markets full-year EBITDA margin18% to 20%FY27 full year
India branded generics₹50–60 crores sales at 35–40% EBITDA; 30–40% Y-o-Y growthFY27 full year
European PIC/S approval for Chhatral facilityProgressing towards approvalQ2–Q3 FY27
Sales and marketing subsidiaries operationalCommence operations and begin scalingH2 FY27
Zoraya and Amerisyn operationalCommence operationsSeptember/October of this year
Sterile injectable pilot project executionExecution beginsLater half of this year
Long-term revenue target₹2,500–3,000 crores with similar or slightly better profitabilityThree to four years
Long-term margin floorAim to sustain 30-odd percent minimumOngoing
Revenue mix (regulated vs. emerging)Remain in the vicinity of 70/30At least the next few years

Key Metrics

MetricQ1 FY27
Revenue from operations₹180 cr, +36% YoY
Regulated markets revenue growth36% YoY
Emerging markets revenue growth~30% YoY
India branded generics revenue₹8 cr
EBITDA₹54 cr, +87% YoY
EBITDA margin~30%, +810 bps YoY
Profit after tax₹31 cr, +56% YoY
FY27 revenue growth guidance30% to 40%
FY27 PAT growth guidance50% to 60%
Approved ANDAs58 as of June 2026, up from 30 as of June 2025
ANDAs commercialized23
ANDAs planned for commercialization35 over next 18 to 20 months
Molecules under development39 molecules, more than 110 strengths
Emerging markets EBITDA marginmid-teens, down from 20% in Q4 FY26 (per an analyst's math)
Emerging markets full-year EBITDA margin guidance18% to 20%
Apnar facility utilization80%–90% of production capacity
FY27 planned capex₹100–120 cr across all subsidiaries
FY28 capex run rate₹60–75 cr minimum
Emerging markets operating cash flow₹18 cr generated in Q1
Emerging markets products under registration942
Long-term revenue target₹2,500–3,000 cr in 3–4 years, with similar or slightly better profitability
Regulated vs emerging markets mix~70/30, expected to remain in this vicinity